23andMe pockets $22M in new venture round

Despite some harsh recent criticism from government regulators on the usefulness and accuracy of its controversial consumer gene tests, the high-profile 23andMe scored a $22 million Series C round. Johnson & Johnson Development Corporation led the round with contributions from New Enterprise Associates and Google Ventures.

"We believe this round of financing will help us achieve our goal of dramatically accelerating the pace of research and could ultimately make health care research and health care delivery more efficient," said Anne Wojcicki, chief executive officer of 23andMe and wife of Google co-founder Sergey Brin.

Over the summer 23andMe along with Navigenics and other gene analysis outfits drew some unwelcome attention from the GAO, which concluded that they were making some poor health predictions based on their tests. 23andMe called the report "flawed." Evidently their financial backers agree.

- here's the 23andMe release for more info

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.